Relative vaccine effectiveness of ChAdOx1/AZD1222 vaccines as booster dose via intradermal injection with a one-fifth dose compared with the intramuscular injection in the prevention of SAR-CoV-2 infections in Phuket: A retrospective cohort study

IF 4.8 2区医学 Q1 INFECTIOUS DISEASES

International Journal of Infectious Diseases Pub Date : 2024-07-31 DOI:10.1016/j.ijid.2024.107179

Withita Jangiam , Kusuma Swangpun , Sopon Iamsirithaworn , Suchanuch Piriyasatit , Dhup Bhukdee

{"title":"Relative vaccine effectiveness of ChAdOx1/AZD1222 vaccines as booster dose via intradermal injection with a one-fifth dose compared with the intramuscular injection in the prevention of SAR-CoV-2 infections in Phuket: A retrospective cohort study","authors":"Withita Jangiam , Kusuma Swangpun , Sopon Iamsirithaworn , Suchanuch Piriyasatit , Dhup Bhukdee","doi":"10.1016/j.ijid.2024.107179","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>This study assessed the real-world relative vaccine effectiveness of the ChAdOx1/AZD1222 vaccine given intradermally at one-fifth dose compared to the standard intramuscular injection, following the completion of 2 doses of CoronaVac, due to limited vaccine availability in Thailand during the Coronavirus disease 2019 (COVID-19) pandemic.</p></div><div><h3>Method</h3><p>This retrospective cohort study used 138,264 records from Vachira Phuket Hospital, Phuket, Thailand. The records were divided into 2 groups: 49,387 recipients received one-fifth doses via intradermal injections, and 88,877 recipients received standard-dose intramuscular injections from September 14 to October 3, 2021, with follow-up until December 31, 2021. Relative vaccine effectiveness for the cohorts was estimated using Cox regression, adjusting for demographic and clinical risk factors.</p></div><div><h3>Results</h3><p>The adjusted hazard ratio between the intradermal and intramuscular groups was 0.88 (95% Confidence Interval 0.76-1.02, <em>P</em> = 0.09), indicating a nonsignificant protective factor for the intradermal group. Further stratified analysis revealed no significant difference between the 2 groups. The 21 and 28-day postvaccination periods minimized the possibility of confounding due to differences in the cohorts’ timeframes.</p></div><div><h3>Conclusion</h3><p>A booster dose of ChAdOx1/AZD1222 given intradermally at one-fifth dose did not show a significant difference compared to the standard intramuscular injection.</p></div>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":4.8000,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1201971224002509/pdfft?md5=e9454ae5011e1f3598e72da1e1bfb4aa&pid=1-s2.0-S1201971224002509-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1201971224002509","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

This study assessed the real-world relative vaccine effectiveness of the ChAdOx1/AZD1222 vaccine given intradermally at one-fifth dose compared to the standard intramuscular injection, following the completion of 2 doses of CoronaVac, due to limited vaccine availability in Thailand during the Coronavirus disease 2019 (COVID-19) pandemic.

Method

This retrospective cohort study used 138,264 records from Vachira Phuket Hospital, Phuket, Thailand. The records were divided into 2 groups: 49,387 recipients received one-fifth doses via intradermal injections, and 88,877 recipients received standard-dose intramuscular injections from September 14 to October 3, 2021, with follow-up until December 31, 2021. Relative vaccine effectiveness for the cohorts was estimated using Cox regression, adjusting for demographic and clinical risk factors.

Results

The adjusted hazard ratio between the intradermal and intramuscular groups was 0.88 (95% Confidence Interval 0.76-1.02, P = 0.09), indicating a nonsignificant protective factor for the intradermal group. Further stratified analysis revealed no significant difference between the 2 groups. The 21 and 28-day postvaccination periods minimized the possibility of confounding due to differences in the cohorts’ timeframes.

Conclusion

A booster dose of ChAdOx1/AZD1222 given intradermally at one-fifth dose did not show a significant difference compared to the standard intramuscular injection.

查看原文本刊更多论文

在普吉岛预防 SAR-CoV-2 感染的过程中，皮内注射五分之一剂量的 ChAdOx1/AZD1222 疫苗与肌肉注射疫苗的相对疫苗效果对比 - 一项回顾性队列研究。

研究目的本研究评估了在泰国冠状病毒病 2019（COVID-19）大流行期间，由于疫苗供应有限，在完成两剂 CoronaVac 后，皮内注射五分之一剂量的 ChAdOx1/AZD1222 疫苗与标准肌肉注射相比在现实世界中的相对疫苗效果：这项回顾性队列研究使用了泰国普吉岛 Vachira Phuket 医院的 138,264 份病历。这些记录被分为两组：49,387 名接种者通过皮内注射接种了五分之一剂量的疫苗，88,877 名接种者在 2021 年 9 月 14 日至 10 月 3 日期间接种了标准剂量的肌肉注射疫苗，随访至 2021 年 12 月 31 日。在对人口统计学和临床风险因素进行调整后，采用考克斯回归法估算了各组群的相对疫苗效力：皮内注射组和肌肉注射组的调整后危险比为 0.88（95% 置信区间为 0.76-1.02，p = 0.09），表明皮内注射组的保护因素不显著。进一步的分层分析显示，两组之间没有明显差异。疫苗接种后21天和28天的接种期最大程度地降低了因组群时间框架不同而造成混杂的可能性：结论：皮内注射五分之一剂量的 ChAdOx1/AZD1222 增强剂与标准肌肉注射相比没有显著差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Infectious Diseases 医学-传染病学

CiteScore

18.90

自引率

2.40%

发文量

1020

审稿时长

30 days

期刊介绍： International Journal of Infectious Diseases (IJID) Publisher: International Society for Infectious Diseases Publication Frequency: Monthly Type: Peer-reviewed, Open Access Scope: Publishes original clinical and laboratory-based research. Reports clinical trials, reviews, and some case reports. Focuses on epidemiology, clinical diagnosis, treatment, and control of infectious diseases. Emphasizes diseases common in under-resourced countries.